| Followers | 145 |
| Posts | 27550 |
| Boards Moderated | 3 |
| Alias Born | 02/07/2004 |
Wednesday, September 23, 2020 11:47:35 AM
MICHAEL KREY10:35 AM ET 09/23/2020
A RedHill Biopharma (RDHL) clinical trial for a Covid-19 treatment will enlist the drug lab-optimized software system made by Veeva Systems (VEEV), sending hot VEEV stock up in premarket trading before slipping at the open.
RedHill plans to use the system in its Phase 2/3 clinical trials to evaluate its treatment opaganib, or Yeliva, for patients hospitalized with severe Covid-19 pneumonia requiring treatment with supplemental oxygen.
Israel-based RedHill also said it would use contract research organization Bioforum to implement and configure Veeva's Vault CDMS software system for its Covid-19 treatment study. RedHill plans to quickly enroll up to 270 patients in 40 clinical sites worldwide. It aims to seek emergency use authorization for opaganib as soon as the fourth quarter of 2020.
https://www.investors.com/news/technology/veev-stock-boosted-covid-19-drug-test-will-use-veeva-systems-software/?src=A00220&yptr=yahoo
Smart move!
Recent RDHL News
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM
Kona Gold Beverages, Inc. Acquires Surge Distribution LLC from Loud Beverage Group, Inc. (LBEV) • KGKG • Apr 16, 2024 8:30 AM
